Subtypes A1 and D, and recombinant HIV-1 natural polymorphisms associated with lenacapavir drug resistance in Uganda
Open Access
- 30 January 2025
- journal article
- research article
- Published by Oxford University Press (OUP) in Journal of Antimicrobial Chemotherapy
- Vol. 80 (4) , 955-961
Abstract
Background: Lenacapavir, a novel HIV-1 capsid inhibitor, shows promise for treating MDR HIV-1, as well as for pre-exposure prophylaxis (PrEP) in prevention of HIV infection. Its unique mechanism and lack of cross-resistance with other antiretroviral classes make lenacapavir a significant addition to HIV therapy. The clinical trials CALIBRATE and CAPELLA have demonstrated high viral suppression rates in both ART-naive individuals and individuals with MDR HIV-1. Lenacapavir-associated resistance mutations, such as M66I and Q67H, rarely seen as natural polymorphisms in lenacapavir-naive populations, are predominantly studied in subtype B HIV-1. Objectives: Our study aimed to investigate the prevalence of lenacapavir resistance-associated mutations in HIV-1 subtypes A1 and D in a cohort of individuals living with HIV-1 from southwestern Uganda. Methods: Utilizing plasma samples from ART-naive adults living in Uganda, HIV-1 Gag p24 (capsid) sequences were analysed for lenacapavir resistance mutations. Results: Among 546 lenacapavir-naive participants, no major lenacapavir resistance-associated mutations were found. Minor mutations were present in 1.6% of participants, with T107A being the most common. Longitudinal data indicated the persistence of T107A for at least 3 years post-ART initiation in one participant. Phylogenetic analysis indicated individuals carrying T107A were found independently in distinct locations within the tree, suggesting that T107A might have arisen from multiple distinct base substitution events. Shannon entropy analysis showed high variability in certain capsid sites, but none overlapped with known lenacapavir resistance sites. Conclusions: These findings suggest a low prevalence of naturally occurring lenacapavir resistance mutations in Uganda, supporting lenacapavir’s potential efficacy in this region.Keywords
Funding Information
- National Institute of Health (R01 MH054907 (D.R.B.), R01 AI162221 (G.Q.L.), R21 AI150398 (G.Q.L.), P30 AI027763 (J.N.M.), K23 AI143470 (S, .M.)])
This publication has 18 references indexed in Scilit:
- Twice-Yearly Lenacapavir or Daily F/TAF for HIV Prevention in Cisgender WomenNew England Journal of Medicine, 2024
- Lenacapavir administered every 26 weeks or daily in combination with oral daily antiretroviral therapy for initial treatment of HIV: a randomised, open-label, active-controlled, phase 2 trialThe Lancet HIV, 2022
- Resistance Analyses in Highly Treatment-Experienced People With Human Immunodeficiency Virus (HIV) Treated With the Novel Capsid HIV Inhibitor LenacapavirThe Journal of Infectious Diseases, 2022
- Capsid Inhibition with Lenacapavir in Multidrug-Resistant HIV-1 InfectionNew England Journal of Medicine, 2022
- Clinical targeting of HIV capsid protein with a long-acting small moleculeNature, 2020
- Frequency of capsid substitutions associated with GS-6207 in vitro resistance in HIV-1 from antiretroviral-naive and -experienced patientsJournal of Antimicrobial Chemotherapy, 2020
- New Algorithms and Methods to Estimate Maximum-Likelihood Phylogenies: Assessing the Performance of PhyML 3.0Systematic Biology, 2010
- Rationale and Uses of a Public HIV Drug‐Resistance DatabaseThe Journal of Infectious Diseases, 2006
- Human immunodeficiency virus reverse transcriptase and protease sequence databaseNucleic Acids Research, 2003
- An improved algorithm for matching biological sequencesJournal of Molecular Biology, 1982